The stock price of Telomir Pharmaceuticals Inc (NASDAQ: TELO) has dropped by -8.95 compared to previous close of 5.03. Despite this, the company has seen a gain of 5.29% in its stock price over the last five trading days. accessnewswire.com reported 2025-02-26 that New Study Confirms Telomir-1 Also Reverses Oxidative Stress, Preserves Cellular Integrity, and Prevents Cell Death by Protecting Mitochondria-The Cell’s Power Source and Gatekeeper of Life and Death MIAMI, FLORIDA / ACCESS Newswire / February 26, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) (“Telomir”), a leader in age-reversal science, today announced compelling new preclinical findings demonstrating that Telomir-1 fully reverses calcium dysregulation-an often-overlooked yet fundamental driver of cell death, aging, and disease progression-in multiple human cell lines.” In addition to restoring calcium homeostasis, the study further confirmed that Telomir-1 reverses oxidative stress and provides robust cellular protection against stress-induced damage.
Is It Worth Investing in Telomir Pharmaceuticals Inc (NASDAQ: TELO) Right Now?
The 36-month beta value for TELO is also noteworthy at -1.99. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for TELO is 17.25M, and at present, short sellers hold a 10.86% of that float. The average trading volume of TELO on March 17, 2025 was 162.98K shares.
TELO’s Market Performance
The stock of Telomir Pharmaceuticals Inc (TELO) has seen a 5.29% increase in the past week, with a 7.76% rise in the past month, and a -17.92% fall in the past quarter. The volatility ratio for the week is 13.07%, and the volatility levels for the past 30 days are at 8.88% for TELO.. The simple moving average for the past 20 days is 7.73% for TELO’s stock, with a -3.88% simple moving average for the past 200 days.
Analysts’ Opinion of TELO
Many brokerage firms have already submitted their reports for TELO stocks, with Rodman & Renshaw repeating the rating for TELO by listing it as a “Buy.” The predicted price for TELO in the upcoming period, according to Rodman & Renshaw is $15 based on the research report published on February 21, 2025 of the current year 2025.
TELO Trading at 3.68% from the 50-Day Moving Average
After a stumble in the market that brought TELO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.22% of loss for the given period.
Volatility was left at 8.88%, however, over the last 30 days, the volatility rate increased by 13.07%, as shares surge +7.26% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -1.29% lower at present.
During the last 5 trading sessions, TELO rose by +5.29%, which changed the moving average for the period of 200-days by -32.05% in comparison to the 20-day moving average, which settled at $4.25. In addition, Telomir Pharmaceuticals Inc saw 11.17% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for TELO
The total capital return value is set at -14.61. Equity return is now at value -813.12, with -544.22 for asset returns.
The liquidity ratio also appears to be rather interesting for investors as it stands at 1.94.
Conclusion
In summary, Telomir Pharmaceuticals Inc (TELO) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
